We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





AACC Disruptive Technology Award Finalists Tackle Cancer, Women's Health, and STDs

By LabMedica International staff writers
Posted on 27 Jul 2022

Biological Dynamics (San Diego, CA, USA), Nanopath (Cambridge, MA, USA) and Visby Medical (San Jose, CA, USA) have been selected as the finalists for AACC’s 2022 Disruptive Technology Award. More...

The three finalists presented early-stage cancer detection technology, point-of-care molecular diagnostics using optical detection, and a rapid sexually transmitted disease assay during the 2022 AACC Annual Scientific Meeting and Clinical Lab Expo. AACC’s Disruptive Technology Award recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing.

Biological Dynamics presented its Verita Isolation Platform, which will become the basis of an annual screening blood test for multiple cancers, according to the company. The platform uses technology for isolating nanoparticles and macromolecules from whole blood, plasma, serum, urine, and saliva. The company recently received an FDA Breakthrough Device Designation for its first liquid biopsy assay that uses the platform for the early detection of pancreatic ductal adenocarcinoma using exosomal proteins.

Nanopath presented its Nanopath Platform, a solid-state biosensing platform with ultrasensitive optical detection. This feature eliminates the need for nucleic acid amplification and provides clinically actionable genetic information in less than 15 minutes. According to the company, the platform should be a “go-to” system for routine women’s health screening at the point of care because it enables high-complexity tests and allows physicians and clinics to get testing revenue. To date, the company has generated preliminary data in two clinical indications: human papillomavirus genotyping and urinary tract infection characterization.

Visby Medical PRC Point-of-Care Tests run on an instrument and cartridge-free, single-use PCR platform that fits in the palm of the hand and delivers accurate results about causes of serious infections in under 30 minutes. The test would eliminate the need to send samples to remote central labs for processing and has been shown to detect DNA from chlamydia, gonorrhea, and trichomoniasis. The platform could benefit patients in remote areas without access to high complexity labs.

Related Links:
Biological Dynamics 
Nanopath 
Visby Medical 


New
Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Alcohol Testing Device
Dräger Alcotest 7000
New
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.